第7章 大腸癌治療薬市場の定性分析

第8章 調査インタビュー

第9章 結論

特許失効およびバイオシミラーの影響

米国：依然として最大の国別市場

APAC：最も速い成長を示す見込み

大腸癌治療薬R&Dパイプライン：混雑しているが、有望な候補薬はいくつあるか？

結論

図表

目次

Product Code: PHA0077

Colorectal Cancer Drugs - Your New Guide to that Market, its R&D and Sales Potentials

Do you want to assess the future of colorectal cancer medicines? Visiongain's new report gives you revenue predictions for that industry from 2015, helping you stay ahead in knowledge and benefit your influence.

In that analysis you see predicted revenues to 2025 at overall world market, geographical and product level. You assess emerging trends, technologies and branded therapies. Explore the future of colorectal cancer drugs and their producers.

With our study, benefit your research, decisions, presentations and influence. Please read on now to discover how our new analysis can help your work.

Interviews with two other authorities - discover opinions to help you stay ahead in knowledge, finding what companies say and do

Analysis of what stimulates and restrains that pharma industry - assess challenges and opportunities, helping you gain advantages and succeed.

What forces stimulate the market for colorectal cancer treating medicines?

In 2015 there exist at least 158 agents in clinical development for colorectal cancer. A large number of those products are in phase II development. Our report helps you understand opportunities in that field and how to use them.

As ageing populations increase, the incidence of cancer rises, leading to rising spending on cancer-treating medicines. That trend will continue. Are you ready for those commercial opportunities? Let our study guide you, showing what is possible.

In our new report you gain 35 charts, 29 tables and two research interviews to help you stay ahead in knowledge.

Forecasts for nine leading drugs - discover sales potentials

Our new investigation gives you revenue forecasts to 2025 for nine leading products for treating colorectal cancer:

Avastin (Roche)

Erbitux (BMS/Merck Serono)

Xeloda (Roche)

Vectibix (Amgen)

Stivarga (Bayer)

Eloxatin (Sanofi)

TS-1 (Taiho Pharmaceuticals)

Zaltrap (Sanofi)

Cyramza (Eli Lilly)

In our work you also see profiles of leading companies and discussions of drugs in development. Our analysis explains activities and prospects of organisations developing, producing and marketing those therapies.

See what the future holds for products treating that disease. Our report explains, from 2015, pharma companies' commercial prospects. Explore what the future holds.

Geographical markets - where lie the best sales and growth potentials?